131 related articles for article (PubMed ID: 2434770)
1. Discovery and therapeutic utility of vasopressin antagonists in rats.
Kinter LB; Dytko G; Ashton D; McDonald J; Huffman W; Stassen F
J Cardiovasc Pharmacol; 1986; 8 Suppl 7():S36-43. PubMed ID: 2434770
[TBL] [Abstract][Full Text] [Related]
2. SK&F 105494: a potent antidiuretic hormone antagonist devoid of partial agonist activity in dogs.
Caldwell N; Brickson B; Kinter LB; Brooks DP; Huffman WF; Stassen FL; Albrightson-Winslow C
J Pharmacol Exp Ther; 1988 Dec; 247(3):897-901. PubMed ID: 3204522
[TBL] [Abstract][Full Text] [Related]
3. Vasopressin antagonism in the squirrel monkey (Saimiri sciureus).
Kinter LB; Churchill S; Stassen FL; Moore M; Huffman W
J Pharmacol Exp Ther; 1987 Jun; 241(3):797-803. PubMed ID: 3598903
[TBL] [Abstract][Full Text] [Related]
4. Antagonism of antidiuretic hormone in domestic pigs (Sus scrofa).
Monaghan ML; Divers T; Huffman WF; Kinter LB
Gen Pharmacol; 1993 Jul; 24(4):1013-20. PubMed ID: 8224729
[TBL] [Abstract][Full Text] [Related]
5. SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatta).
Brooks DP; Koster PF; Albrightson-Winslow CR; Stassen FL; Huffman WF; Kinter LB
J Pharmacol Exp Ther; 1988 Apr; 245(1):211-5. PubMed ID: 3361442
[TBL] [Abstract][Full Text] [Related]
6. Effect of the vasopressin antagonist d(CH2)5 Tyr(Et)VAVP on diuresis in rat.
László FA; Csáti S; Baláspiri L; Manning M
Acta Med Hung; 1984; 41(1):65-73. PubMed ID: 6739224
[TBL] [Abstract][Full Text] [Related]
7. A novel radiolabeled vasopressin antagonist: [3H-Phe]-desGlyd(CH2)5D-Tyr(Et)VAVP, [3H]-SK&F 101926.
Stassen FL; Heckman G; Schmidt D; Nambi P; Aiyar N; Landvatter S; Crooke ST
Mol Pharmacol; 1987 Mar; 31(3):267-72. PubMed ID: 2951585
[TBL] [Abstract][Full Text] [Related]
8. An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.
Manning M; Cheng LL; Stoev S; Bankowski K; Przybyiski J; Klis WA; Sawyer WH; Wo NC; Chan WY
J Pept Sci; 1995; 1(1):66-79. PubMed ID: 9222985
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of renal adenylate cyclase-coupled vasopressin receptors after chronic administration of vasopressin antagonists to rats.
Caltabiano S; Kinter LB
J Pharmacol Exp Ther; 1991 Sep; 258(3):1046-54. PubMed ID: 1832462
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of action and structural requirements of vasopressin analog inhibition of transepithelial water flux in toad urinary bladder.
Mann WA; Stassen F; Huffman W; Kinter LB
J Pharmacol Exp Ther; 1986 Aug; 238(2):401-6. PubMed ID: 3090234
[TBL] [Abstract][Full Text] [Related]
11. Effect of the vasopressin antagonist d/CH2/5Tyr/Et/VAVP on the antidiuretic action of exogenous and endogenous vasopressin.
László FA; Csáti S; Baláspiri L
Acta Endocrinol (Copenh); 1984 May; 106(1):52-5. PubMed ID: 6730854
[TBL] [Abstract][Full Text] [Related]
12. Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone.
Sawyer WH; Pang PK; Seto J; McEnroe M; Lammek B; Manning M
Science; 1981 Apr; 212(4490):49-51. PubMed ID: 7209515
[TBL] [Abstract][Full Text] [Related]
13. C-terminal deletions in agonistic and antagonistic analogues of vasopressin that improve their specificities for antidiuretic (V2) and vasopressor (V1) receptors.
Manning M; Misicka A; Olma A; Klis WA; Bankowski K; Nawrocka E; Kruszynski M; Kolodziejczyk A; Cheng LL; Seto J
J Med Chem; 1987 Dec; 30(12):2245-52. PubMed ID: 2960812
[TBL] [Abstract][Full Text] [Related]
14. Physiological regulation of the renal vasopressin receptor-effector pathway in dogs.
Kinter LB; Caldwell N; Caltabiano S; Winslow C; Brooks DP; Huffman WF
Am J Physiol; 1990 Mar; 258(3 Pt 2):R763-9. PubMed ID: 2138428
[TBL] [Abstract][Full Text] [Related]
15. Effect of cyclo-oxygenase blockade on the renal actions of vasopressin and SK&F 105494 in the rhesus monkey.
Brooks DP; Caldwell NC; Koster PF; Albrightson-Winslow CR; Kinter LB
Br J Pharmacol; 1990 Apr; 99(4):750-2. PubMed ID: 2113824
[TBL] [Abstract][Full Text] [Related]
16. Further in vivo evidence for antagonist-to-antidiuretic action of arginine vasopressin.
Ishikawa S; Kim JK; Schrier RW
Am J Physiol; 1983 Nov; 245(5 Pt 1):R713-9. PubMed ID: 6688929
[TBL] [Abstract][Full Text] [Related]
17. Prevention of hyponatraemia and cerebral oedema by the vasopressin antagonist d/CH2/5Tyr/Et/VAVP in rats treated with pitressin tannate.
László FA; Csáti S; Baláspiri L
Acta Endocrinol (Copenh); 1984 May; 106(1):56-60. PubMed ID: 6730855
[TBL] [Abstract][Full Text] [Related]
18. Arginine vasopressin increases renal sodium excretion in the anesthetized rat through V1 receptors.
Musabayane CT; Forsling ML; Balment RJ
Ren Fail; 1997 Jan; 19(1):23-32. PubMed ID: 9044449
[TBL] [Abstract][Full Text] [Related]
19. Synthetic antagonists of in vivo antidiuretic and vasopressor responses to arginine-vasopressin.
Manning M; Lammek B; Kolodziejczyk AM; Seto J; Sawyer WH
J Med Chem; 1981 Jun; 24(6):701-6. PubMed ID: 7252979
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase inhibition unmasks the full antidiuretic agonist activity of the vasopressin antagonist, SK&F 101926, in dogs.
Albrightson-Winslow CR; Caldwell N; Brooks DP; Huffman WF; Stassen FL; Kinter LB
J Pharmacol Exp Ther; 1989 May; 249(2):366-71. PubMed ID: 2524585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
